Cortexyme, Inc. (CRTX)
Market Cap | 1.10B |
Revenue (ttm) | n/a |
Net Income (ttm) | -68.67M |
Shares Out | 29.49M |
EPS (ttm) | -2.35 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 26 |
Last Price | $37.36 |
Previous Close | $31.66 |
Change ($) | 5.70 |
Change (%) | 18.00% |
Day's Open | 31.81 |
Day's Range | 31.73 - 38.75 |
Day's Volume | 582,251 |
52-Week Range | 27.78 - 72.51 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...
CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash.
Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...
Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with A...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
The 2020 year is practically halfway done, and this has really been the year of the biotech.
Cortexyme: A New Approach To Defeat Alzheimer's Disease
A promising new approach could potentially yield a new drug providing hope for millions of Alzheimer's patients worldwide.
Cortexyme (NASDAQ: CRTX) is a clinical stage bio-pharmaceutical company working on Alzheimer’s and other degenerative diseases. The company currently has one molecule in its pipeline, called C...
Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...
2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.
About CRTX
Cortexyme, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Industry Biotechnology | IPO Date May 9, 2019 |
CEO Casey C. Lynch | Employees 23 |
Stock Exchange NASDAQ | Ticker Symbol CRTX |
Analyst Forecasts
According to 8 analysts, the average rating for Cortexyme stock is "Buy." The 12-month stock price forecast is 75.75, which is an increase of 102.76% from the latest price.